There were fewer FGFR2+ GC patients with PD-L1 expression (CPS ≥ 1) (4/9 cases, 44.4%) than those with a CPS indicating negative PD-L1 expression (5/9 cases, 55.6%), whereas FGFR2− GC patients, including a substantial number of cases with a CPS, indicate positive PD-L1 expression (CPS ≥ 1; 120/171 cases, 70.1%) (Figures 4(d), bottom panel, and 4(f)). The gene discussed is FGFR2; the disease is gastric cancer.